Isoray, Inc. (ISR)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.3075 |
| Open | 0.3028 |
| Bid | 0.3011 x 45100 |
| Ask | 0.3150 x 1100 |
| Day's Range | 0.2986 - 0.3200 |
| 52 Week Range | 0.2500 - 0.9400 |
| Volume | |
| Avg. Volume | 367,191 |
| Market Cap | 42.731M |
| Beta (5Y Monthly) | 0.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings Date | Feb 07, 2022 - Feb 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.08 |
- Zacks
IsoRay (ISR) Reports Q3 Loss, Lags Revenue Estimates
IsoRay (ISR) delivered earnings and revenue surprises of 0% and 7.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Isoray Announces Record Third Quarter Fiscal 2022 Financial Results
Revenue Increased 12% Year-Over-YearRecord Non-Prostate Brachytherapy Revenue Increased 28% Year-Over-Year RICHLAND, Wash., May 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced its financial results for the third quarter of fiscal 2022 ended March 31, 2022. Revenue for the third quarter of fiscal 2022 grew 12% to $2.91 million versus $2.60 million in the prior year comparable period. The Company’s co
- Zacks
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of -5.26% and 6.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
